inhaled corticosteroids: doubled doses of little value in asthma

Inpharma 1422 - 31 Jan 2004 Inhaled corticosteroids: doubled doses of little value in asthma There is little evidence to recommend doubling the dose of inhaled corticosteroids when asthma control starts to deteriorate, according to the results of a UK- based study. The randomised controlled trial involved 390 primary- care patients (aged ≥ 16 years) with asthma who were regularly taking an inhaled corticosteroid (100–2000 µg/day) and who had temporarily doubled their dose or received oral corticosteroids over the previous year to treat or prevent an asthma exacerbation. Patients received corticosteroids to double their usual dose (n = 192) or placebo, administered via inhalers, in addition to their usual treatment for 14 days if their asthma deteriorated. * A 10-day course of prednisolone was started if their asthma control deteriorated to the point where they normally commence oral corticosteroids, or if their peak flow decreased by 40% from the mean run-in value. The primary endpoint of the study was the proportion of patients who required prednisolone in each study group. Over a 12-month period, the study inhaler was used by 110 patients in the active group and 97 in the placebo group. Of these, 19 patients (17%) in the active group and 22 patients (23%) in the placebo group started prednisolone treatment (risk ratio 0.8; 95% CI 0.45–1.4). Doubling the dose of inhaled corticosteroid resulted in a small reduction in the mean maximum fall in peak flow of –10 L/minute compared with placebo (p = 0.07); however, there were no between-group differences in the rise in symptom scores, time to recovery for peak flow and symptom scores, lowest peak flow recorded or highest symptom score recorded. Similar results were observed in a subgroup of patients receiving lower doses of inhaled corticosteroids (≤ 1000 µg/day). * if their daytime score increased by one point from the mean peak flow and median symptom score during a 2-week run-in period, or their morning peak flow fell by 15% Harrison TW, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363: 271-275, No. 9405, 24 Jan 2004 800943986 1 Inpharma 31 Jan 2004 No. 1422 1173-8324/10/1422-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 13-Dec-2016

213 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Inpharma 1422 - 31 Jan 2004

Inhaled corticosteroids: doubleddoses of little value in asthma

There is little evidence to recommend doubling thedose of inhaled corticosteroids when asthma controlstarts to deteriorate, according to the results of a UK-based study.

The randomised controlled trial involved 390 primary-care patients (aged ≥ 16 years) with asthma who wereregularly taking an inhaled corticosteroid(100–2000 µg/day) and who had temporarily doubledtheir dose or received oral corticosteroids over theprevious year to treat or prevent an asthmaexacerbation. Patients received corticosteroids todouble their usual dose (n = 192) or placebo,administered via inhalers, in addition to their usualtreatment for 14 days if their asthma deteriorated.* A10-day course of prednisolone was started if theirasthma control deteriorated to the point where theynormally commence oral corticosteroids, or if their peakflow decreased by 40% from the mean run-in value. Theprimary endpoint of the study was the proportion ofpatients who required prednisolone in each studygroup.

Over a 12-month period, the study inhaler was usedby 110 patients in the active group and 97 in the placebogroup. Of these, 19 patients (17%) in the active groupand 22 patients (23%) in the placebo group startedprednisolone treatment (risk ratio 0.8; 95%CI 0.45–1.4). Doubling the dose of inhaledcorticosteroid resulted in a small reduction in the meanmaximum fall in peak flow of –10 L/minute comparedwith placebo (p = 0.07); however, there were nobetween-group differences in the rise in symptomscores, time to recovery for peak flow and symptomscores, lowest peak flow recorded or highest symptomscore recorded. Similar results were observed in asubgroup of patients receiving lower doses of inhaledcorticosteroids (≤ 1000 µg/day).* if their daytime score increased by one point from the mean peakflow and median symptom score during a 2-week run-in period, ortheir morning peak flow fell by 15%

Harrison TW, et al. Doubling the dose of inhaled corticosteroid to prevent asthmaexacerbations: randomised controlled trial. Lancet 363: 271-275, No. 9405, 24 Jan2004 800943986

Inhaled corticosteroids in clinical practice

Inhaled Corticosteroids and the Risk of Pneumonia Tobias Welte Department of Respiratory Medicine

Inhaled corticosteroids in COPD: Determinants of use and ...downloads.hindawi.com/journals/crj/2004/289420.pdf · Despite the controversy over inhaled corticosteroids in COPD, prescription

Monitoring long-term oral corticosteroids · corticosteroids are absorbed systemically and are therefore more likely to cause adverse effects than topical or inhaled corticosteroids

Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease A National Cohort Study

Inhaled Corticosteroids in Asthma - KoreaMed · Inhaled Corticosteroids in Asthma I z] ... systemic effects of the drugs were a major obstacle to use them in asthma therapy. A

SGA 2003-W-286750-SS Slide 1 Dual Pathways of Asthmatic Inflammation Montelukast with Inhaled Corticosteroids

Breathomics for Assessing the Effects of Treatment and ... · Keywords: breathomics, inhaled corticosteroids, long-acting β2-agonists, COPD, pharmacotherapy INTRODUCTION Respiratory

Lea Bentur, MD Pediatric Pulmonary Unit Inhaled corticosteroids in preschool asthmatic children. Is it really needed?? OR Can inhaled corticosteroids change

The use of inhaled corticosteroids in pediatric asthma: update

Long-acting Beta-agonists and Inhaled Corticosteroids for ... COPD Final.p… · TITLE: Long-acting Beta-agonists and Inhaled Corticosteroids for Treatment of Chronic Obstructive

Inhaled corticosteroids for the treatment of chronic asthma in